Background-Failure ofthe donor (graft) heart is the main cause of mortality in the first month after orthotopic cardiac transplantation. In a preliminary study marked downregulation of cardiac fp adrenoceptor density was found in apparently normal donor hearts ofrecipients who developed severe cardiac failure soon after implantation. Cardiac fl adrenoceptors are an important factor in the development of cardiac failure in the human heart. The aim of this study therefore was to determine whether fatal graft failure in the first month after transplantation is associated with downregulation of fl adrenoceptor density in the donor heart. Patients and methods-Right ventricular endomyocardial biopsy specimens were taken from consecutive adult donor patients immediately before implantation. A previously described radioligand binding method was used to determine fl adrenoceptor density in consecutive patients who developed fatal graft failure and died within 1 month of transplantation and in a group of control donors transplanted during the same period. Results-Perioperative fatal graft failure developed in 13 patients. Forty one specimens from donor hearts that were transplanted into recipients who did not develop fatal graft heart failure formed the control group. There were no systematic differences in donor or recipient characteristics between the graft heart failure and control groups. In particular donor catecholamine requirement and recipient pulmonary vascular resistance did not differ between groups. Total p adrenoceptor density was reduced in the fatal graft heart failure group compared with that in the controls (13.4 (7) fmollmg v 21 (7) fmollmg; P < 0.01). There was a positive correlation between p adrenoceptor density in the donor heart and time to death in the graft heart failure group (r2 = 0-3, P < 0.05). The p adrenoceptor binding affinity (Kd) did not differ between the graft failure group and the controls (47 (6) pM v 44 (7) pM). Conclusion-The development of perioperative fatal cardiac failure after orthotopic cardiac transplantation is associated with downregulation of 8l adrenoceptors in the donor heart before implantation. (Br Heart 1995;73:540-543) Keywords: human cardiac transplantation; ,B adrenoceptor downregulation; cardiac failure Graft heart failure unrelated to rejection, infection, or raised pulmonary vascular resistance in the recipient is the main cause of death in the perioperative period after orthotopic transplantation.' During the development of a new method for analysing /3 adrenoceptor binding affinity in human myocardial biopsy tissue,2 we observed that /3 adrenoceptor density was markedly reduced in apparently normal donor hearts of recipients who unexpectedly developed severe intractable graft heart failure that was unresponsive to escalating doses of catecholamines and died soon after implantation.
marked downregulation of cardiac fp adrenoceptor density was found in apparently normal donor hearts ofrecipients who developed severe cardiac failure soon after implantation. Cardiac fl adrenoceptors are an important factor in the development of cardiac failure in the human heart. The aim of this study therefore was to determine whether fatal graft failure in the first month after transplantation is associated with downregulation of fl adrenoceptor density in the donor heart. Patients and methods-Right ventricular endomyocardial biopsy specimens were taken from consecutive adult donor patients immediately before implantation. A previously described radioligand binding method was used to determine fl adrenoceptor density in consecutive patients who developed fatal graft failure and died within 1 month of transplantation and in a group of control donors transplanted during the same period. Results-Perioperative fatal graft failure developed in 13 patients. Forty one specimens from donor hearts that were transplanted into recipients who did not develop fatal graft heart failure formed the control group. There were no systematic differences in donor or recipient characteristics between the graft heart failure and control groups. In particular donor catecholamine requirement and recipient pulmonary vascular resistance did not differ between groups. Total p adrenoceptor density was reduced in the fatal graft heart failure group compared with that in the controls (13.4 (7) fmollmg v 21 (7) fmollmg; P < 0.01). There was a positive correlation between p adrenoceptor density in the donor heart and time to death in the graft heart failure group (r2 = 0-3, P < 0.05). records were reviewed blind to the fi adrenoceptor data. The diagnosis of primary cardiac failure was considered firm if made by a consultant experienced in transplantation management. Otherwise, the diagnosis was made, in the absence of bleeding, tissue rejection, or septicaemia, if there was clear evidence of intractable haemodynamic deterioration despite inotropic support and associated worsening radiological pulmonary oedema or increased pulmonary artery wedge pressure, and the patient died without recovering. Thus, recipients in whom the primary cause of death was considered to be other than cardiac failure were included in the control group.
METHODS
Membrane preparation and the radioligand binding method have been described previously.5
Protein concentrations were assayed in duplicate using the Lowry method with bovine serum albumin as standard. 6 fi adrenoceptor density and the equilibrium dissociation constant (Kd) were analysed in all specimens using non-linear regression (7) pM). There was no relation between ischaemic time and ,l adrenoceptor density (y = 0 01x + 18, r2 = 0-01, P = 0-65).
There was a positive correlation between donor 16 adrenoceptor density and time to death in the graft heart failure group (y = lx + 7, r2 = 0.3, P = 0.044).
Discussion
This study, based on a chance observation in a previous study,5 shows for the first time that the development of intractable graft failure and death soon after transplantation is associated with downregulation of 16 adrenoceptor density in the right ventricular endomyocardium of brain dead donor hearts before implantation.
Graft heart failure is a major cause of perioperative mortality after cardiac transplantation.' Several studies have identified abnormalities in the recipient, such as raised pulmonary vascular resistance and inotropic requirement, that are associated with graft failure and poor outcome after implantation.89
Darracott-Cankovic and colleagues'0-have shown that apparently "normal" donor hearts may be functionally impaired. Furthermore, these authors observed a correlation between myocardial injury in the donor heart at transplantation and increased early mortality after transplantation." All donor hearts in our study were obtained from previously normal patients with brain death. Experimental models have demonstrated that brain death can induce myocardial damage through over activation of the sympathoadrenergic pathway. '2 There is extensive clinical evidence that "sympathetic storm" after brain damage also produces myocardial injury in humans"3-"5 and is accompanied by excess catecholamine release.'6 Overall downregulation of cardiac 16 adrenoceptor after increased sympathetic stimulation and catecholamine exposure is well recognised in humans and is associated with impaired systolic function in heart failure.' 718 Thus the findings in our study are consistent with the notion that donor hearts that developed graft failure may have been exposed to excess catecholamines before explantation. Whether this relates to a centrally mediated "sympathetic storm" after brain death is speculative. Certainly, there was no obvious clinical or electrocardiographic evidence of such a process operating in the graft failure group in our study. Selective 16 adrenoceptor subtype blockade during cerebral injury has shown that centrally mediated myocardial damage is predominantly through the 16l adrenoceptor subtype.'9 Such a mechanism might be expected to selectively downregulate 16, adrenoceptors. We assessed 16, and 162 adrenoceptor subtype density in a few specimens (five of the graft heart failure group and 13 of the controls) using CGP 20712A as described previously.20 There was a trend towards a relative reduction in the 16' subtype in the graft failure group (56 (4)%) compared with that in the controls (65 (3)%) (P = 0 08).
In clinical practice intensive care patients rarely die from cardiac failure alone. Multisystem failure usually intervenes in extremis, as was the case in our patients. It is therefore highly unlikely that downregulation of 16 adrenoceptor per se can account for the increased mortality in the graft failure group. Indeed, there is considerable overlap in 16 adrenoceptor density between the graft failure group and the controls. Furthermore, the observed positive correlation between 16 adrenoceptor density and survival time in the graft failure group should be interpreted with caution because of the relatively small numbers of patients with fatal graft failure. Whether downregulation of 16 adrenoceptor has a role in the development of graft failure or whether downregulation reflects a pathological process in the donor that contributes to mortality is speculative.
The absolute values in the literature for 16 adrenoceptor density in normal hearts vary considerably. There was possibly a loss of receptors in our study during the period between organ harvesting and biopsy procurement (ischaemic time). There was no correlation, however, between ischaemic time and 16 adrenoceptor density in this study and 
Conclusion
This study has demonstrated a hitherto unrecognised association between downregulation of fi adrenoceptor density in the apparently normal donor heart and the development of fatal graft heart failure after implantation. The study shows that better methods of evaluation to improve the prognosis of recipients are needed and that further research in the area of donor heart evaluation is warranted. Finally, the study brings into question the validity of using unused brain dead donor hearts as "normal" controls in studies of fi adrenoceptor function and regulation in the human heart.4 51721 We thank Professor Sir Magdi H Yacoub for allowing us access to the patients analysed in this study. MRC was supported by a British Heart Foundation research fellowship grant.
